(Albany, US) September 22, 2026 – DelveInsight’s “Netherton Syndrome Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Netherton Syndrome pipeline landscape. It covers the Netherton Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Netherton Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Netherton Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight
Key Takeaways from the Netherton Syndrome Pipeline Report
- In August 2026- Quoin Pharmaceuticals initiated a clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (including up to the entire body [except the scalp]) works to treat the genetic disease Netherton syndrome.
- DelveInsight’s Netherton Syndrome Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Netherton Syndrome treatment.
- The leading Netherton Syndrome Companies, such as TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma and others.
- Promising Netherton Syndrome Therapies such as QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others.
Want to know which companies are leading innovation in Netherton Syndrome? Dive into the full pipeline insights @ Netherton Syndrome Clinical Trials Assessment
The Netherton Syndrome Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Netherton Syndrome Pipeline Report also highlights the unmet needs with respect to the Netherton Syndrome.
Netherton Syndrome Overview
Netherton syndrome is a rare, severe autosomal recessive genodermatosis characterized by impaired skin barrier function, chronic inflammation, and atopic manifestations. It is caused by pathogenic variants in the SPINK5 gene, which encodes the serine protease inhibitor lymphoepithelial Kazal-type-related inhibitor (LEKTI). The disorder typically presents at birth or during early infancy with generalized erythroderma, recurrent skin infections, and failure to thrive. Affected individuals often exhibit a lifelong predisposition to allergic diseases, including asthma, food allergies, allergic rhinitis, and elevated serum IgE levels. Although uncommon, the disease imposes significant morbidity due to persistent skin inflammation, infections, nutritional deficiencies, and reduced quality of life.
Netherton Syndrome Emerging Drugs Profile
- QRX003: Quoin Pharmaceuticals
QRX003 (proposed brand name: QYLEKI™) is an investigational 4% topical lotion being developed by Quoin Pharmaceuticals for the treatment of Netherton syndrome, a rare genetic skin disorder caused by SPINK5 mutations. The therapy is designed to restore skin barrier function by locally inhibiting excessive serine protease activity, thereby reducing inflammation, skin scaling, erythema, pruritus, and transepidermal water loss. QRX003 is administered twice daily over affected skin and has demonstrated encouraging safety and clinical improvements in ongoing studies, including pediatric patients. The product has received Orphan Drug Designation (US, EU, Japan), as well as FDA Fast Track and Rare Pediatric Disease designations. Quoin’s pivotal Phase III study is expected to initiate in the second half of 2026 and a potential NDA filing is anticipated in 2027. Currently, the drug is being studies in a Phase II/III clinical trial for the treatment of Netherton syndrome.
If you’re tracking ongoing Netherton Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Netherton Syndrome Treatment Drugs
The Netherton Syndrome Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Netherton Syndrome with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Netherton Syndrome Treatment.
- Netherton Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Netherton Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Netherton Syndrome market.
Netherton Syndrome Companies
TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma and others.
Netherton Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Netherton Syndrome Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
From emerging drug candidates to competitive intelligence, the Netherton Syndrome Pipeline Report covers it all – check it out now @ Netherton Syndrome Market Drivers and Barriers, and Future Perspectives
Scope of the Netherton Syndrome Pipeline Report
- Coverage- Global
- Netherton Syndrome Companies- TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma and others.
- Netherton Syndrome Therapies- QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others.
- Netherton Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Netherton Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what’s next for the Netherton Syndrome Treatment landscape in this detailed analysis @ Netherton Syndrome Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Netherton Syndrome: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Netherton Syndrome – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II/III)
- QRX003: Quoin Pharmaceuticals
- Early Stage Products (Phase I/II)
- SXR-1096: Sixera Pharma
- Preclinical and Discovery Stage Products
- Inactive Products
- Netherton Syndrome Key Companies
- Netherton Syndrome Key Products
- Netherton Syndrome Unmet Needs
- Netherton Syndrome Market Drivers and Barriers
- Netherton Syndrome Future Perspectives and Conclusion
- Netherton Syndrome Analyst Views
- Netherton Syndrome Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/netherton-syndrome-pipeline-insight